Actinium Pharmaceuticals (ATNM) Other Accumulated Expenses (2021 - 2022)
Actinium Pharmaceuticals (ATNM) posted quarterly Other Accumulated Expenses of $934000.0 for Q4 2022, up 92.18% year-over-year from $486000.0 in Q4 2021, and up 926.37% quarter-over-quarter from $91000.0 in Q3 2022.
Actinium Pharmaceuticals (ATNM) Other Accumulated Expenses (2021 - 2022) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Other Accumulated Expenses for 2 consecutive years, with $934000.0 the latest figure, recorded in Q4 2022.
- In Q4 2022, Other Accumulated Expenses rose 92.18% year-over-year to $934000.0; the TTM figure through Dec 2022 stood at $934000.0 (up 92.18% YoY), while the FY2022 annual figure was $934000.0, up 92.18% from the prior year.
- Other Accumulated Expenses rose to $934000.0 in Q4 2022 per ATNM's latest filing, from $91000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $934000.0 in Q4 2022 and bottomed at $91000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 934,000.00 |
| Sep 30, 2022 | 91,000.00 |
| Jun 30, 2022 | 204,000.00 |
| Mar 31, 2022 | 267,000.00 |
| Dec 31, 2021 | 486,000.00 |